EE200300083A - Bitsüklilised pürrooli amiidid kui glükogeeni fosforülaasi inhibiitorid - Google Patents

Bitsüklilised pürrooli amiidid kui glükogeeni fosforülaasi inhibiitorid

Info

Publication number
EE200300083A
EE200300083A EEP200300083A EEP200300083A EE200300083A EE 200300083 A EE200300083 A EE 200300083A EE P200300083 A EEP200300083 A EE P200300083A EE P200300083 A EEP200300083 A EE P200300083A EE 200300083 A EE200300083 A EE 200300083A
Authority
EE
Estonia
Prior art keywords
glycogen phosphorylase
phosphorylase inhibitors
pyrrole amides
bicyclic pyrrole
amide derivatives
Prior art date
Application number
EEP200300083A
Other languages
English (en)
Estonian (et)
Inventor
B. Bartlett Julie
Freeman Sue
Kenny Peter
Morley Andrew
Whittamore Paul
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200300083A publication Critical patent/EE200300083A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200300083A 2000-09-06 2001-08-31 Bitsüklilised pürrooli amiidid kui glükogeeni fosforülaasi inhibiitorid EE200300083A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0021831.3A GB0021831D0 (en) 2000-09-06 2000-09-06 Chemical compounds
PCT/SE2001/001880 WO2002020530A1 (en) 2000-09-06 2001-08-31 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors

Publications (1)

Publication Number Publication Date
EE200300083A true EE200300083A (et) 2004-12-15

Family

ID=9898927

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300083A EE200300083A (et) 2000-09-06 2001-08-31 Bitsüklilised pürrooli amiidid kui glükogeeni fosforülaasi inhibiitorid

Country Status (31)

Country Link
US (1) US20030232875A1 (de)
EP (1) EP1317459B1 (de)
JP (1) JP2004508376A (de)
KR (1) KR100802369B1 (de)
CN (2) CN1896078A (de)
AT (1) ATE263772T1 (de)
AU (2) AU2001282833B2 (de)
BG (1) BG107624A (de)
BR (1) BR0113606A (de)
CA (1) CA2417594A1 (de)
CZ (1) CZ2003616A3 (de)
DE (1) DE60102710T2 (de)
DK (1) DK1317459T3 (de)
EE (1) EE200300083A (de)
ES (1) ES2217183T3 (de)
GB (1) GB0021831D0 (de)
HK (1) HK1055299A1 (de)
HU (1) HUP0400784A3 (de)
IL (1) IL154291A0 (de)
IS (1) IS2110B (de)
MX (1) MXPA03001512A (de)
NO (1) NO20031024D0 (de)
NZ (1) NZ524011A (de)
PL (1) PL361024A1 (de)
PT (1) PT1317459E (de)
RU (1) RU2003104013A (de)
SK (1) SK2592003A3 (de)
TR (1) TR200401659T4 (de)
UA (1) UA73781C2 (de)
WO (1) WO2002020530A1 (de)
ZA (1) ZA200301013B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
GB0205165D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
DE10215908B4 (de) * 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
IL164249A0 (en) * 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
DE10225635C1 (de) * 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
EP1375477B1 (de) * 2002-06-17 2009-09-30 Saltigo GmbH Verfahren zur Herstellung von mono-N-sulfonylierten Diaminen
MXPA05000055A (es) * 2002-07-11 2005-04-08 Aventis Pharma Gmbh Acilureas sustituidas con urea y uretano, metodos para su produccion y su uso.
EP1388535A1 (de) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylierte Arylcycloalkylamine und ihre Anwendung als Arzneimittelwirkstoff
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
MXPA05004968A (es) 2002-11-07 2005-08-02 Pfizer Prod Inc N-(indol-z-carbonil)amidas como agentes anti-diabeticos.
EP1620427A1 (de) * 2003-04-17 2006-02-01 Pfizer Products Inc. Carbonsäureamid-derivate als antidiabetika
UA84146C2 (ru) * 2003-05-21 2008-09-25 Прозидион Лимитед Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
WO2004113345A1 (ja) * 2003-06-20 2004-12-29 Japan Tobacco Inc. 縮合ピロール化合物及びその医薬用途
GB0318464D0 (en) * 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0318463D0 (en) * 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds
GB0319690D0 (en) * 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
GB0319759D0 (en) * 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
WO2005020985A1 (en) * 2003-08-29 2005-03-10 Astrazeneca Ab Indolamide derivatives which possess glycogen phosphorylase inhibitory activity
WO2005020986A1 (en) * 2003-08-29 2005-03-10 Astrazeneca Ab Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
GB0320422D0 (en) * 2003-08-30 2003-10-01 Astrazeneca Ab Chemical compounds
CZ2006427A3 (cs) 2003-12-29 2006-11-15 Sepracor Inc. Pyrrolové a pyrazolové inhibitory DAAO
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
PL1819704T3 (pl) 2004-12-02 2008-12-31 Prosidion Ltd Amidowe pochodne kwasu pirolopirydyno-2-karboksylowego użyteczne jako inhibitory fosforylazy glikogenowej
ATE506951T1 (de) 2005-01-19 2011-05-15 Merck Sharp & Dohme Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
EP1848693A1 (de) * 2005-02-05 2007-10-31 AstraZeneca AB Indanamidderivate mit glykogenphosphorylase hemmender wirkung
CA2595835A1 (en) * 2005-02-05 2006-08-10 Astrazeneca Ab Chemical compounds
AU2007205114B2 (en) 2006-01-06 2012-11-08 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
ES2566479T3 (es) 2006-01-06 2016-04-13 Sunovion Pharmaceuticals Inc. Inhibidores de reabsorción de monoamina con base en tetralona
CN101421228B (zh) 2006-03-31 2014-05-21 塞普拉柯公司 手性酰胺和胺的制备
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
WO2008047821A1 (fr) * 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Composé hétérocyclique fusionné
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
US8669291B2 (en) 2007-05-31 2014-03-11 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100152200A1 (en) * 2008-11-17 2010-06-17 The Regents Of The University Of Michigan Alphavirus inhibitors and uses thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3004138B1 (de) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultrareine agonisten von guanylatcyclase c, verfahren zur herstellung und verwendung davon
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
TWI763630B (zh) * 2015-07-02 2022-05-11 瑞士商赫孚孟拉羅股份公司 雙環內醯胺及其使用方法
CR20180413A (es) * 2016-02-05 2018-12-04 Denali Therapeutics Inc Inhibidores de la proteína quinasa 1 que interactua con el receptor
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
WO2019204537A1 (en) 2018-04-20 2019-10-24 Genentech, Inc. N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
CN113302189A (zh) 2018-11-20 2021-08-24 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
EP4066896A4 (de) * 2019-11-27 2024-03-27 Riken G9a-inhibitor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706810A (en) * 1970-09-15 1972-12-19 American Cyanamid Co N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4599198A (en) * 1985-08-02 1986-07-08 Pfizer Inc. Intermediates in polypeptide synthesis
US4668769A (en) * 1985-08-02 1987-05-26 Hoover Dennis J Oxa- and azahomocyclostatine polypeptides
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
FR2601368B1 (fr) * 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
DE3629545A1 (de) * 1986-08-30 1988-03-10 Bayer Ag Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung
US4751231A (en) * 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
ES2081747B1 (es) * 1993-09-07 1997-01-16 Esteve Labor Dr Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos.
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
FR2723739B1 (fr) * 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
US6107329A (en) * 1995-06-06 2000-08-22 Pfizer, Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
AU2825899A (en) * 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
EP1088824B1 (de) * 1999-09-30 2004-01-07 Pfizer Products Inc. Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use

Also Published As

Publication number Publication date
ATE263772T1 (de) 2004-04-15
EP1317459A1 (de) 2003-06-11
US20030232875A1 (en) 2003-12-18
JP2004508376A (ja) 2004-03-18
CN1473163A (zh) 2004-02-04
RU2003104013A (ru) 2004-08-20
DE60102710D1 (de) 2004-05-13
KR20030025305A (ko) 2003-03-28
TR200401659T4 (tr) 2004-09-21
NO20031024L (no) 2003-03-05
PL361024A1 (en) 2004-09-20
IS6727A (is) 2003-02-24
EP1317459B1 (de) 2004-04-07
CA2417594A1 (en) 2002-03-14
HK1055299A1 (en) 2004-01-02
PT1317459E (pt) 2004-08-31
AU8283301A (en) 2002-03-22
GB0021831D0 (en) 2000-10-18
UA73781C2 (en) 2005-09-15
MXPA03001512A (es) 2003-06-09
KR100802369B1 (ko) 2008-02-14
ES2217183T3 (es) 2004-11-01
IS2110B (is) 2006-05-15
ZA200301013B (en) 2004-05-05
HUP0400784A2 (hu) 2004-07-28
DE60102710T2 (de) 2005-04-14
NZ524011A (en) 2004-08-27
CN1264846C (zh) 2006-07-19
HUP0400784A3 (en) 2007-09-28
AU2001282833B2 (en) 2006-07-06
BR0113606A (pt) 2003-06-24
IL154291A0 (en) 2003-09-17
DK1317459T3 (da) 2004-07-12
SK2592003A3 (en) 2003-08-05
BG107624A (bg) 2004-01-30
CZ2003616A3 (cs) 2003-05-14
CN1896078A (zh) 2007-01-17
WO2002020530A1 (en) 2002-03-14
NO20031024D0 (no) 2003-03-05

Similar Documents

Publication Publication Date Title
EE200300083A (et) Bitsüklilised pürrooli amiidid kui glükogeeni fosforülaasi inhibiitorid
NO986055L (no) Nye heterocykliske forbindelser, deres fremstilling, farmas°ytiske preparater inneholdende forbindelsene og deres anvendelse ved behandling av diabetes og beslektede sykdommer
TW200504067A (en) New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
EA200300205A1 (ru) Производные пиразола и их применение в качестве ингибиторов протеинкиназы
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
GEP20084357B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
BR0214277A (pt) Solvatos de paclitaxel
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
DE60045508D1 (de) Dalda-analoge und ihre verwendung
WO2004043337A3 (en) Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
HK1075450A1 (en) heterocyclic compunds, process for their preparation and pharmaceutical compositions containing thenm and thier use in medicine
DE59509846D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
DE59510370D1 (de) [a]-ANNELIERTE PYRROLDERIVATE UND DEREN ANWENDUNG IN DER PHARMAZIE
ATE291018T1 (de) Pyrazol verbindungen und ihre verwendung
MXPA05013210A (es) Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos.
WO2003074513A3 (en) Indole amide derivatives and their use as glycogen phosphorylase inhibitors
ZA961069B (en) Heterocyclic derivatives
MXPA05012953A (es) Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
EP1812007A4 (de) Pyridazinverbindungen und verfahren
CA2534634A1 (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors
ATE440835T1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
AP2000001760A0 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase.
TW200510370A (en) Urea derivatives
DK1104419T3 (da) N-substituerede azabicyloheptan-derivater, deres fremstilling og anvendelse
SE9902596D0 (sv) Pharmaceutically active compounds